Grace Therapeutics, Inc.
GRCE
$3.16
$0.020.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.96M | 2.14M | 1.55M | 1.51M | 1.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.53M | 3.09M | 3.18M | 3.70M | 4.83M |
| Operating Income | -2.53M | -3.09M | -3.18M | -3.70M | -4.83M |
| Income Before Tax | -938.00K | -3.36M | -382.00K | -4.76M | -4.28M |
| Income Tax Expenses | -- | -- | -1.02M | -605.00K | -852.00K |
| Earnings from Continuing Operations | -938.00K | -3.36M | 636.00K | -4.16M | -3.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -938.00K | -3.36M | 636.00K | -4.16M | -3.43M |
| EBIT | -2.53M | -3.09M | -3.18M | -3.70M | -4.83M |
| EBITDA | -2.53M | -3.09M | -3.18M | -3.70M | -4.83M |
| EPS Basic | -0.06 | -0.21 | 0.05 | -0.36 | -0.30 |
| Normalized Basic EPS | -0.04 | -0.13 | -0.02 | -0.26 | -0.23 |
| EPS Diluted | -0.06 | -0.21 | 0.05 | -0.36 | -0.30 |
| Normalized Diluted EPS | -0.04 | -0.13 | -0.02 | -0.26 | -0.23 |
| Average Basic Shares Outstanding | 15.92M | 15.92M | 13.83M | 11.51M | 11.51M |
| Average Diluted Shares Outstanding | 15.92M | 15.92M | 13.83M | 11.51M | 11.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |